Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates CGEM Bullish with a Setup Score of 0, net conviction 52, actionability 0. How the Setup Score works →
| Total Setup Score | 0 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 52 |
| Actionability | 0 (in range) |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in … Read full Trend Edge analysis →
| Current Price | $18.13 |
|---|---|
| Market Cap | $1.13B |
| Float | 44.2M |
| Shares Outstanding | 61.5M |
| P/E (Forward) | 6.74 |
| Price/Sales (TTM) | 25.86 |
| vs. Analyst Target | +74.0% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $31.55 (9 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $18.9M | -$50.8M | -$62,000 | -$60.3M |
| 2021 | $18.9M | -$65.0M | $18.9M | -$67.9M |
| 2022 | N/A | $111M | -$93,000 | -$132M |
| 2023 | N/A | -$153M | -$310,000 | -$190M |
| 2024 | N/A | -$167M | -$306,000 | -$167M |
| 2025 | N/A | -$220M | -$311,000 | -$220M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | N/A | -$70.1M |
| Sep 2025 | N/A | -$50.6M |
| Dec 2025 | N/A | -$50.7M |
| Mar 2026 | N/A | -$49.7M |
| Insider Ownership | 0.4% |
|---|---|
| Institutional Ownership | 107.7% |
| Short Float | 18.5% |
| % of All Funds Holding | 1.90% |
| Number of Funds Holding | 156 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $15.70 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $12.56 | Medium-term trend |
| Weekly | 80-Week SMA | $10.43 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $12.29 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $13.79 | Near-term monthly trend |
| Monthly | 20-Month SMA | $11.12 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $12.85 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $13.00 | support | 1.17x | 1 months ago |
| $12.20 | support | 1.00x | 4 months ago |
| $8.60 | support | 1.73x | 7 months ago |
| $6.00 | support | 2.85x | 8 months ago |
| $22.80 | resistance | 2.03x | 24 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.18% | 0.27% | 63.64% | 4.45% | -9.04% |
| 1 Day | 0.93% | 1.17% | 54.55% | 18.00% | -10.89% |
| 1 Week | -1.31% | -3.62% | 40.91% | 26.00% | -15.23% |
| 2 Weeks | 1.24% | 1.30% | 54.55% | 28.84% | -19.51% |
| 1 Month | 2.65% | -5.10% | 42.86% | 72.67% | -37.09% |
Next earnings: August 6, 2026 (24 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | 0.04% | 46.1% | 256 |
| Tuesday | 0.16% | 50.5% | 285 |
| Wednesday | -0.03% | 47.3% | 283 |
| Thursday | -0.05% | 45.3% | 276 |
| Friday | 0.17% | 49.3% | 276 |
Institutional holder breakdown coming soon.
Total institutional ownership: 107.7%
Total insider ownership: 0.4%
Founder-led management: Patrick Baeuerle (Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board)
| Total Filings | 25 |
|---|---|
| Net Value | -$1.6M |
| Net Shares Change | 1,766,145 |
| % of Float | 4.0% |
| C-Suite Filings | 22 |
| Clusters Detected | 2 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Lynx1 Capital Management LP | +$13.3M | 3 | 3 buy | |
| AHMED NADIM | President and CEO | -$418,671.27 | 2 | 2 sell |
| Jones Jeffrey Alan | Chief Medical Officer | -$134,156.38 | 2 | 2 sell |
| SUMER JACQUELYN L | Chief Legal Officer | -$103,072.51 | 2 | 2 sell |
| Fenton Mary Kay | Chief Financial Officer | -$59,900.76 | 1 | 1 sell |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2025-12-16 – 2025-12-29 | 6 | 4 | -$257,681.974 | 6 C-suite |
| 2026-02-13 – 2026-02-26 | 11 | 5 | -$953,557.662 | 11 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2025-10-10 | Lynx1 Capital Management LP | +$9.8M | Transaction at $6.73, now +169.3% | |
| 2026-02-25 | SUMER JACQUELYN L | Chief Legal Officer | -$52,106.47 | Transaction at $14.47, now +25.3% |
| 2026-02-25 | Jones Jeffrey Alan | Chief Medical Officer | -$66,301.54 | Transaction at $14.47, now +25.3% |
| 2026-02-25 | AHMED NADIM | President and CEO | -$195,562.05 | Transaction at $14.47, now +25.3% |
| 2026-02-23 | SUMER JACQUELYN L | Chief Legal Officer | -$50,966.04 | Transaction at $13.62, now +33.1% |
| 2026-02-23 | Jones Jeffrey Alan | Chief Medical Officer | -$67,854.84 | Transaction at $13.62, now +33.1% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Cullinan Oncology LLC (CGEM) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for CGEM on Trend Edge →